A b s t r a c t
Prostate cancer is the most frequent new cancer diagnosis in American men, and the disease incidence increases with age more than any other cancer. 1, 2 During the past 15 years, in the era of serum prostate-specific antigen (PSA) screening, there has been a significant increase in the detection of prostate cancer. [3] [4] [5] [6] Prostate cancer is widely known to vary substantially in aggressiveness. [7] [8] [9] [10] [11] [12] [13] Given the significant potential morbidity associated with aggressive treatment, there has been significant interest in the development of traditional morphologic feature-based and newer molecular-based prognostic factors that potentially could distinguish the indolent cases unlikely to progress during a man's remaining lifetime from the invasive tumors capable of distant metastasis and producing androgenindependent, antiandrogen-resistant fatal disease. [7] [8] [9] [10] [11] [12] [13] 
Morphologic Feature-Based Prognostic Factors
The pathologic staging and microscopic grading of prostate cancer are widely accepted as major morphologydriven prognostic factors for the disease. 14 Additional morphologic markers include vascular space involvement and mitotic activity. In an attempt to stratify the potential clinical usefulness of prognostic and predictive factors, the College of American Pathologists has proposed classifying them into the following categories: category I, markers that are well supported by the literature and generally used in patient management; category II, markers that are extensively studied biologically and/or clinically but with few clinical outcome studies; and category III, markers that currently do not meet the criteria of category I or II. 15 The College of American Pathologists classification of prognostic factors in prostate cancer is summarized in ❚Table 1❚. Serum has been treated with estrogens. [24] [25] [26] Signet-ring cell carcinomas are negative for neutral and acid mucins, immunoreactive for PSAP and PSA, and clinically aggressive. 27, 28 Small cell and neuroendocrine carcinomas are associated with a uniformly poor prognosis. 29 Prostatic transitional cell carcinomas arise from the periurethral glandular epithelium or from metaplastic prostatic epithelium, are negative for PSA and PSAP, and often develop into aggressive tumors that do not respond to hormonal therapy. 16, 30 Lymphoepithelioma-like carcinomas are poorly differentiated carcinomas with a syncytial growth pattern, prominent lymphocytic stroma, and adverse clinical behavior. 16 Carcinosarcomas and sarcomatoid carcinomas are rapidly progressive biphasic tumors featuring a sarcomatous component. 16, 31, 32 Basal cell carcinomas and carcinoid tumors are additional rare prostatic neoplasms with adverse clinical outcomes. 33 
Tumor Grade
The microscopic grade of a prostate cancer correlates significantly with the local extent of the disease, incidence of lymph node and bone metastasis, response to various therapies, and overall disease outcome. [6] [7] [8] [9] [10] [11] [12] [13] The 2-grade summation scoring system developed by Gleason 34 has correlated with cell proliferation rate, aneuploid DNA content, oncogene activation, and tumor suppressor gene mutation [6] [7] [8] [9] [10] [11] [12] [13] and is predictive of rapid PSA progression. 35 However, although the Gleason score of prostatic adenocarcinoma is clearly one of the strongest predictors of biologic behavior and metastatic potential, in most studies, it does not seem to be capable of predicting disease outcome when used alone. [6] [7] [8] [9] [10] [11] [12] [13] The correlation of Gleason score for the needle biopsy specimen with the final score at radical prostatectomy is best for moderately and poorly differentiated adenocarcinomas. 36 Discrepancies between the Gleason score for biopsy specimens and corresponding radical prostatectomy specimens are greatest when Gleason scores are low and the quantity of tumor in the biopsy specimens is limited. 37 In addition, it has been documented that grading accuracy for needle biopsy specimens might be higher when the grading pathologists are experienced subspecialists in urologic pathology. 38 This may be manifest in the higher incidence of grade changes, upward or downward, at radical prostatectomy encountered when community hospital pathologists performed the original biopsy grading. 38 Foci of Gleason patterns 4 and 5 seem to be predictive of adverse outcome even when present in only a minute or tertiary focus. 39, 40 
Tumor Volume
Tumor volume is a significant predictor of pathologic stage, lymph node and distant metastasis, and overall disease outcome. 34, [41] [42] [43] The number and length of involvement of multiple (sextant or octant) needle biopsy cores has been successful at predicting overall tumor volume, pathologic stage, and disease outcome. 44 
Tumor Stage
Extraprostatic extension is reportedly very common in prostatic adenocarcinoma, with an incidence as high as 90% in 1 series. 45, 46 Patients with focal intracapsular penetration by the tumor are reported to have an intermediate prognostic risk between those with organ-confined disease and those with diffuse extraprostatic extension. 47 The presence of perineural invasion in the needle biopsy specimen has been reported to be a specific marker for capsular penetration of the tumor in a prostatectomy specimen, 48 although the overall prognostic significance of perineural invasion remains controversial. 49 Seminal vesicle involvement by prostate cancer is associated with high tumor grade, large tumor volume, extraprostatic extension, lymph node metastasis, and poor prognosis. 50 Positive margins of resection significantly affect disease outcome and correlate with high preoperative serum PSA levels, high tumor grade, and aneuploid DNA content. 47,51-53 Vascular space invasion also has been associated with disease progression. 54 The presence of nodal metastases is highly associated with significant tumor progression, with an overall incidence averaging 40%. 55 Recent studies of micrometastasis detection using molecular methods have differed in their conclusions. 56,57 Bone metastases might signify the progression to androgen-independent tumor growth and, with liver and other parenchymal metastases, often herald progression to an ultimate fatal disease outcome.
Molecular-Based Prognostic and Predictive Factors
A variety of ancillary procedures and molecular-based assays of genes and proteins (Table 1) have been studied for their ability to predict outcome and target therapy in prostate cancer. [6] [7] [8] [9] [10] [11] [12] [13] 58, 59 Tumor-Specific Proteins Immunohistochemical staining and other methods designed to detect the cellular expression levels of PSA and PSAP have not been successful generally for predicting outcome in prostate cancer. [6] [7] [8] [9] [10] [11] [12] [13] However, in a recent study using fine-needle aspiration biopsy specimens and immunocytochemical analysis, loss of cellular PSA staining successfully predicted disease progression independent of clinical stage, cytologic grade, and DNA ploidy status in patients after endocrine therapy. 60 Although individual cell anti-PSA immunostaining decreases with tumor dedifferentiation, prostate-specific membrane antigen (PSMA) staining is maintained in both low-and high-grade tumors, including primary and metastatic lesions. 61 In a recent study using prostatectomy specimens, increased PSMA expression ❚Image 1❚ was associated with biochemical disease relapse. 62 Anti-PSMA staining also has been described in the endothelium of tumor blood vessels in carcinomas of other primary sites, including breast, colon, and lung. 63 Prostate stem cell antigen seems to maintain or increase staining intensity in high-grade tumors and has been correlated with advanced stage and bone metastasis. 64, 65 
Nuclear Hormone Receptors
Although androgen receptor (AR) loss and clinical lack of benefit from antiandrogen therapy have been associated with high-grade and high-stage prostate cancer, AR activity has not independently predicted disease-related death. 66 AR expression can be heterogeneous in prostate cancer, which might reflect AR genetic instability and the future development of androgen-independent tumor growth. 67 Assays of AR activity have not been used to select patients for androgen ablation therapy before prostatectomy. Research interest in AR activity has focused on the relationship between expression of various growth factors and matrix metalloproteinases associated with prostate cancer progression and AR status. 13, 68 Although the development of androgen-independent tumor growth has been associated with various specific point mutations in the AR gene, disease outcome has not correlated with AR expression. 13 Further characterization of AR activity in prostate cancer seems warranted to better understand the events that produce the capability of androgen-independent growth for some aggressive tumors and the interaction of AR with other prognostic markers.
Cell Proliferation Markers
Cell proliferation has been measured in prostate cancer by immunohistochemical staining using cell proliferation markers and by the calculation of the S phase from flow cytometry or image analysis-derived quantitative DNA histograms. Immunohistochemical analysis using the MIB-1/Ki-67 antibody is the technique of choice for measuring cell cycle progression in processed human tissues. 69, 70 A proliferative index of more than 16% MIB-1 staining has been associated with a highly adverse prognosis. [69] [70] [71] [72] [73] [74] MIB-1 overexpression ❚Image 2❚ also has been associated with primary therapy failure 70 and has predicted prognosis even in patients with existing lymph node involvement. 75 In contrast with other malignancies, S-phase calculations by flow cytometric analysis or image analysis have been less clinically useful in prostate cancer.
A ❚Image 1❚ A, Intense prostate-specific membrane antigen (PSMA) overexpression detected by immunohistochemical analysis in a patient with a pathologic stage III, Gleason score 7 tumor that progressed to hormone refractory metastatic disease (anti-PSMA with 7E11 antibody, immunoperoxidase with hematoxylin counterstain, ×200). B, PSMA messenger RNA overexpression (white areas) detected by in situ hybridization, autoradiography, and darkfield illumination (PSMA sulfur 35-labeled antisense probe, ×100).
B
❚Image 2❚ Prostate cancer cell proliferation index determined by immunostaining for the MIB-1/Ki-67 proliferation marker. The labeling index for this case was 7%. This is a relatively high rate of proliferation for prostate cancer and is associated with a higher grade and a higher stage of disease with a propensity for recurrence after surgical or radiation therapy (antihuman Ki-67, diaminobenzidine, hematoxylin, ×400).
Cell Cycle Regulators

Cyclins
Cell cycle regulatory proteins have been linked to adverse outcome in prostate cancer. 13 Cyclin D1 overexpression has been detected in approximately 10% of prostate cancers and has been linked to the development of bone metastases. 76 
Cyclin-Dependent Kinase Inhibitors
In the G 1 to S phase transition of the cell cycle, 2 families of cyclin-dependent kinase inhibitors have been described: the Cip/Kip and INK4 groups. 13 Both p21 and p27 proteins, members of the Cip/Kip family, have been studied as prognostic factors in prostate cancer. 13 Maintenance of p21 immunoreactivity is associated with prolonged disease-free survival. 77 Loss of p27 expression has been associated with adverse disease outcome in a number of studies. 13, [78] [79] [80] In addition, the homeobox protein skp-2 has been shown to be expressed ❚Image 3❚ inversely to p27 in prostate cancer and might represent a drug target candidate for the disease. 81 The p16 INK4 tumor suppressor gene is rarely mutated in prostate cancer, but decreased protein expression has been associated with gene deletions and promoter hypermethylation. 82 Interestingly, increased p16 immunostaining has been associated with the presence of prostate cancer, but this marker has not become a useful prognostic factor to date. 79 Overexpression of p34 cdc2 cyclindependent kinase, involved in the S to G 2 M transition of the cell cycle, has been associated with aggressive high-grade disease featuring an increased incidence of biochemical failure after primary therapy. 83 
DNA Ploidy Determination
The majority of retrospective studies have shown that aneuploid DNA content in prostate cancer independently predicts a poor prognosis for the disease. [84] [85] [86] [87] [88] [89] DNA ploidy measurements have been performed on needle biopsy specimens by using the tissue section image analysis technique 90 ❚Image 4❚. An aneuploid DNA ploidy status determined on needle biopsy specimens has correlated successfully with the ploidy status of corresponding radical prostatectomy specimens and independently predicted disease outcome. 90 DNA ploidy determination on needle biopsy specimens has been used to confirm biopsy grading, 91 although this role is reduced substantially when grading of the biopsy specimen is performed by experts. 92 
Molecular Genetics and Cytogenetics
A variety of molecular and cytogenetic abnormalities have been associated with prostate cancer. 93 Although certain loci have been associated with the incidence of familial prostate cancer, disease heterogeneity has impeded the discovery of predisposition genes. 13 The most frequent sites of losses of genetic material in prostate cancer, in decreasing order, are on chromosomes 13q, 8p, 6q, 5q, 16q, 18q, 2q, 4q, 10q, and Y. 12 The most frequent gains are seen on chromosomes 8q, 17q, Xq, 7q, 3q, 9q, 1q, and Xp. 12 Chromosomal loss at 8p22 with concurrent gain of 8c 94 and 13q21 95 have been associated with adverse disease outcome. Also, loss at 8p21, the site of a prostate-specific homeobox gene NKX3.1, also has correlated with tumor progression. 96 Comparative genomic hybridization studies of prostate cancer have found DNA copy number changes in as many as 65% of the analyzed tumors, with the most common chromosomal losses found at regions 13q21q33 (29%), 6q11q23 (24%), 16q, and 18 (each 18%) and the most common gains at 19 (18%). 97 
Morphometrics
A variety of morphometric techniques have been applied on prostate cancer specimens with the nuclear roundness factor measurement achieving the most significant potential clinical usefulness. Prostate cancers featuring almost perfectly round nuclei typically are well-differentiated and slow-growing cancers. Tumors with irregular nuclear contours and correspondingly low nuclear roundness have been associated with high tumor grade and a propensity for the development of distant metastasis and shortened survival. [98] [99] [100] [101] A recent study of morphometric features in prostate cancer found that suboptimal circle fit and Feret diameter ratio measurements could predict disease relapse after radiation therapy. 101 ❚Image 3❚ Expression of p27 in prostate cancer. This welldifferentiated tumor abundantly expressed p27, was nonimmunoreactive for skp-2, and featured no evidence of biochemical disease relapse more than 5 years after primary prostatectomy (peroxidase-antiperoxidase ×200).
Tumor Vascularity and Microvessel Density
Tumor angiogenesis also has correlated with adverse outcome in prostate cancer as measured by microvessel counting studies. 102 Significantly higher microvessel counts have been obtained in areas of adenocarcinoma than in the benign tissues of radical prostatectomy specimens. 103 Prostate cancers seem to have the greatest concentration of microvessels in the centers of the tumoral areas, which might account for the infrequency of necrosis in prostate cancer. 104 Increased microvascularity has been found to correlate with the pathologic stage of the disease. 102, 105, 106 Microvessel density has been associated with the presence of metastasis 102 and with a significant risk for disease progression after radical prostatectomy in some studies 105, [107] [108] [109] but has failed to achieve significance as an outcome predictor in others. 110 These conflicting results might reflect methodological differences in microvessel counting techniques. The application of microvessel counts to prostate cancer needle biopsy specimens, in which the counts could be used prospectively to plan therapy, has not received sufficient study.
Color Doppler flow has been shown to be an important aid to gray-scale sonography in the detection of prostatic carcinoma and has been correlated with tumor grade and stage. [110] [111] [112] [113] [114] [115] However, little evidence has been presented to date linking sonographic findings to microvessel counts in the respective tissue samples. In fact, in 1 study, microvessel density and tumor size were no different in specimens with normal or with increased color Doppler flow. 114 
Nuclear Matrix Proteins
Nuclear matrix proteins function to maintain the structure, shape, and higher order of DNA organization within a cell. 116 Nuclear matrix proteins have been characterized in prostate cancer and may define subsets of the disease with differing biology and clinical behavior. 116 The expression of 1 nuclear matrix protein, YL-1, seems to be related to an aggressive type of prostate cancer and correlates with pathologic stage of disease. 117 
Cytokines
In hormone-refractory prostate cancer, up-regulation of inflammation-associated interleukin (IL)-4, IL-6, and IL-10 has been described. 118 Recently, serum IL-6 levels have been linked to adverse outcome. 119 Tissue-based cytokine measurements have not been associated with prostate cancer prognosis.
Growth Factors
A variety of growth factors have been studied in prostate cancer, including the epidermal growth factor (EGF) and its receptor (EGFR). The results have been conflicting, ie, although EGF assays of prostate cancer specimens show higher levels than seen in the normal prostate, high-grade ❚Image 4❚ DNA ploidy in prostate cancer. A, In this Gleason score 6 prostate cancer needle biopsy specimen (H&E, ×100), the DNA ploidy histogram (inset) determined by the tissue section image analysis technique revealed a diploid pattern with a DNA index of 1.06. B, In this Gleason score 7 needle biopsy specimen (H&E, ×100), the histogram (inset) shows a tetraploid aneuploid pattern with DNA index of 2.06. Ploidy patterns of needle biopsy specimens have been correlated with postprostatectomy disease relapse and also can be used to confirm the accuracy of tumor grading. Needle biopsy specimens featuring a low histologic grade and an aneuploid histogram are significantly more likely to be upgraded on the radical prostatectomy specimen (see text). tumors seem to have lower EGF content than do well-differentiated lesions. 120 Increased EGFR expression has been linked to progression to androgen-independent disease in 1 study, 121 and preclinical studies have suggested that anti-EGFR therapies, such as with small molecule tyrosine kinase inhibitor ZD1839 (Iressa, Astra Zeneca, Manchester, England), have possible clinical usefulness in treatment. 122 Increased expression of basic fibroblast growth factor has been linked to adverse outcome. 59 Overexpression of transforming growth factor β has been implicated in the growth of prostate cancer cell lines 13 and a significant reduction in disease-free survival in clinical trials. 123 Up-regulation of vascular endothelial growth factor in prostate cancer has been associated with adverse outcome in patients with clinically localized disease. 124 Growth factors seem to operate in networks in the prostate, and further studies are necessary to elucidate the various interactions of these trophic proteins on disease outcome.
Cell Adhesion Molecules
Loss of expression of E-cadherin, a cell adhesion molecule, has been associated with adverse disease outcome in prostate cancer. [125] [126] [127] [128] [129] [130] Decreased expression of E-cadherin has been shown to associate with high tumor grade and aneuploidy. 131 It has been further suggested that this deletion might involve the E-cadherin gene and that E-cadherin protein, in addition to its cell adhesion role, might be functioning as a tumor suppressor protein. Alternatively, the loss of E-cadherin expression in prostate cancer might be related to gene methylation ❚Image 5❚. 132 Further immunohistochemical and molecular genetic studies seem warranted to pursue this potential important association.
The E-cadherin interaction with β-catenin has received substantial study resulting from the linkage of β-catenin degradation and association with the APC gene. 13 Expression of β-catenin on the cytoplasmic membrane indicates Ecadherin interaction, whereas transfer of β-catenin staining to the cytoplasm and nucleus indicates that β-catenin has initiated signal transduction mediated by the lymphoid enhancer factor complex, which has been associated with the up-regulation of various genes associated with adverse prognosis, such as cyclin D1. 133 Anomalies of β-catenin expression have been described in prostate cancer and have been associated with disease progression. 134 The CD44 cell adhesion molecule also has been linked to outcome in prostate cancer. Loss of expression of the CD44 protein standard form has been associated with other adverse prognostic factors such as high tumor grade and aneuploid DNA content. 135, 136 Recent evidence points to promoter gene hypermethylation as the cause of the loss of CD44 standard form expression in prostate cancer. 137 CD44 also is associated with production of a series of splice variant proteins that have been linked to adverse outcome in a variety of malignant neoplasms, including prostate cancer. 138 The expression of CD44v6 might be a predictor of poor prognosis in organ-confined prostate cancer and useful for planning adjuvant therapy. 138 Integrins have been studied widely in prostate cancer and implicated as potential indicators of aggressive disease. 136, 139 Decreased expression of the α 4 integrin subunit and the laminin 5 subunit have been linked to adverse disease outcome. 59
Tumor Invasion-Associated Proteases
Cathepsin D, a lysosomal protease and autocrine mitogen, has been associated with prognosis in breast cancer. 140 In prostate cancer, increased tumor cathepsin D immunoreactivity has been correlated with pathologic stage 141 and with tumor grade and DNA content. 142 Increased serum levels of soluble urokinase plasminogen activator receptor have been linked to progressive prostate cancer. 143 Finally, localization of tumor collagenases 59 and matrix metalloproteinases has been linked to the development and progression of prostate cancer. 144, 145 
Dominant Oncogenes
In comparison with their significance in adenocarcinomas of the respiratory and gastrointestinal tracts, the roles of dominant oncogenes in the development and progression of prostate cancer seem limited. 59 commonly mutated in epithelial adenocarcinomas in the gastrointestinal, hepatobiliary, and respiratory tracts, are not altered frequently in human prostate cancers, cell lines, or experimental models. 148 Amplification of the myc gene has been studied in prostate cancer but could not be linked to disease progression. 148 Mutations of myc might be associated with the development of hormone-refractory disease. 149
The HER-2/neu (c-erb-b2) Gene
The presence of HER-2/neu (c-erb-b2) gene amplification or overexpression of the protein has been associated with adverse outcome in breast cancer, and testing for HER-2 has achieved standard-of-practice status for selecting therapy for breast cancer patients. 150 For prostate cancer, the results of immunohistochemical analysis-based studies have conflicted but generally favor that overexpression of the HER-2/neu protein is associated with an adverse outcome. [151] [152] [153] [154] The results of fluorescence in situ hybridization-based studies also have varied, with some finding extra copies of the gene in hormone-naive [155] [156] [157] and hormonetreated cases 158 and others not detecting amplification. 159 HER-2/neu messenger RNA (mRNA) levels have been correlated with metastatic disease and androgen-independent, hormone-refractory, progressive disease. 159 Early clinical trials using the humanized anti-HER-2/neu monoclonal antibody trastuzumab (Herceptin) have not shown significant responses. 160 Other anti-HER-2/neu-targeted therapies for prostate cancer are in early clinical development.
Tumor Suppressor Genes p53
The assessment of p53 status in prostate cancer has included both molecular techniques (single-strand conformation polymorphism and direct sequencing) and immunohistochemical analysis (multiple methods and reagents). Positive immunostaining for p53 has been associated with the detection of the more stable mutant protein and predicts the presence of p53 gene mutation with about 80% to 90% accuracy. 161 By using a variety of antibodies and immunohistochemical techniques, p53 protein expression has been reported frequently in prostate cancer, with average immunoreactivity ranging from 13% to 23%. 162 A positive association between nuclear p53 immunoreactivity and aggressive biologic behavior of prostate cancer has been confirmed in multiple studies. [163] [164] [165] [166] [167] [168] [169] [170] Mutations of p53 seem to be frequent in metastatic prostate cancer. 171 Although immunohistochemical analysis can be an inaccurate predictor of p53 gene status, when molecular biologic techniques are used, it has been reported that 42% of prostate cancers can harbor mutant p53 sequences. 172 Mutations of the p53 locus in benign prostate tissue have been reported, suggesting that p53 mutations might occur early in the pathogenesis of prostate cancer. 173, 174 New studies of p53 status, including functional assays, must be performed on needle biopsy specimens to achieve prognostic value for prospective treatment planning in prostate cancer.
PTEN/AKT-1
The PTEN (phosphatase and tensin homolog deleted from chromosome 10) also known as MMAC1 (mutated in multiple advanced cancers 1) tumor suppressor gene is deleted or mutated in a wide variety of malignant neoplasms and in prostate cancer cell lines, xenografts, and clinical samples. 13, 175, 176 Loss of expression of PTEN has been associated with down-regulation of the cyclin-dependent kinase inhibitor p27 and adverse outcome with increasing tumor grade and stage in prostate cancer. 79, 81, [175] [176] [177] p16
Abnormal expression of the G 1 -S cell cycle regulator p16 has been detected in prostate cancer clinical samples. 178 Inactivation of p16 in prostate cancer has been associated with methylation of the promoter region of the p16 gene with silencing of mRNA and protein production. 179, 180 Recently, the loss of expression of p16 has been associated with prostate cancer progression, metastasis, and disease relapse. 82, 181, 182 
KAI-1
The KAI-1 gene, mapped to chromosome 11p, has been implicated as a tumor suppressor gene in prostate cancer, but altered expression of this gene has not been associated with prognosis. 59, 183, 184 pRB
The retinoblastoma gene on chromosome 13 also might function as a tumor suppressor in prostate cancer, but probably is altered in only a small subset of cases. 185, 186 The immunohistochemical staining score independently predicted disease outcome in 1 study. 187 Other known tumor suppressor genes that might have a role in prostatic carcinogenesis but have not been linked to disease outcome are the DCC (deleted in colorectal cancer) gene on chromosome 18q and the APC (adenomatous polyposis coli) gene on chromosome 5q. 186 The APC gene might be important, however, in its association with degradation of the β-catenin protein and blockade of β-catenin-mediated nuclear transcription of cell cycle promoters such as cyclin D1.
Drug-Resistance Genes
Multidrug Resistance
The multidrug resistance factor has been implicated as having a role in the development of resistance of metastatic prostate cancer to conventional cytotoxic chemotherapy. 188 The expression of the multidrug resistance biomarker Pglycoprotein was correlated with tumor grade, stage, and PSA levels in one study 186 and with tumor stage in another. 189 
Glutathione-S-Transferase-π
The glutathione-S-transferase (GST)-π gene is involved in the intracellular detoxification of drugs and toxins. GST-π is deactivated in the vast majority of prostatic carcinomas by the hypermethylation of CpG island promoter sequences, resulting in loss of expression of the GST-π protein. 190, 191 Although it has little value as a prognostic factor, GST-π methylation detection shows substantial promise as a urine-, semen-, or blood-based assay for the detection of prostate cancer. [192] [193] [194] The high frequency of GST-π gene silencing by methylation also has raised the possibility that this biomarker could be the target of a chemoprevention program for prostate cancer. 195 
Apoptosis and bcl-2
Expression of bcl-2 has been studied in prostate cancer, initially by immunohistochemical techniques, and found to react with primary and metastatic prostate cancer specimens obtained from patients with tumors refractory to hormonal therapy. 196 Immunoreactivity for bcl-2 is most intense in basal cells rather than secretory cells 197 and may be limited to normal prostatic and seminal vesicle epithelium and to rare cases of poorly differentiated but not well-differentiated prostatic carcinomas. 198 In prostate cancer, overexpression of bcl-2 protein is not associated with rearrangements in the 2.8-kilobase major breakpoint region or with accumulation of p53 protein. 199 Several studies have linked the overexpression of the bcl-2 antiapoptosis protein with decreased expression of the proapoptotic protein bax and adverse outcome in prostate cancer associated with resistance to cytotoxic chemotherapy in patients with hormone-refractory disease. 13, 200, 201 Other studies, however, have not found prognostic significance for bcl-2 expression. 202, 203 Telomerase Telomerase activity, measured by the telomere amplification protocol assay, is present in virtually all prostate cancers, with increasing levels associated with high-grade disease. [204] [205] [206] Telomerase detection has been advocated as a potential technique to confirm the presence of microfoci of prostate cancer in needle biopsy specimens. 204, 205 Telomerase measurements have been tested for their ability to assess the status of surgical resection margins after prostatectomy. 207 Molecular methods also have featured telomerase testing as a means to detect prostate cancer in seminal fluid. 192, 208 However, given its wide expression range in most prostate cancers, the measurement of telomerase has not been useful as a prognostic factor, although it has been linked to high-grade disease. 209 
Microsatellite Instability
Microsatellite instability (MSI) has not been studied widely in prostate cancer. Initial studies of clinical specimens failed to demonstrate widespread MSI. 210 Additional studies suggested that MSI might be related to early prostate cancer development, 211 and a recent study linked MSI and hMSH2 gene expression to biochemical disease relapse. 212 
Unclassified Biomarkers
Human Glandular Kallikrein 2
The human glandular kallikrein (hK) family of proteins includes PSA, which also is known as hK3. 213 This secreted protein recently has shown promise for improving the specificity of serum-based prostate cancer screening compared with serum PSA levels. [214] [215] [216] To date, hK2 expression in prostate cancer tissue has not been linked to prognosis.
Hepsin-like Protease
By using transcriptional profiling, in addition to hK2, PSA (hK3), and PSMA, hepsin, a serine protease also known as hepsin-like protease, is a highly overexpressed mRNA that is particularly characteristic of high-grade tumors. [217] [218] [219] Most recently, overexpression of hepsin mRNA detected by expression profiling on DNA microarrays has been associated with adverse disease outcome in prostate cancer. 220, 221 α-Methylacyl-Coenzyme A Racemase Numerous recent transcriptional profiling studies of prostate cancer specimens have detected significant up-regulation of α-methylacyl-coenzyme A racemase (AMACR), a peroxisomal and mitochondrial enzyme. [221] [222] [223] Although AMACR expression has been linked to prostate cancer differentiation, it has not been identified as a prognostic marker for the disease. 224 Most recently, AMACR immunostaining has been used to identify minute foci of prostate cancer in needle biopsy specimens, with variable results. 225 
Nuclear Factor κ κB and the Proteasome
The nuclear transcription factor κB (NFκB) complex has a role in cancer development and progression through its influence on apoptosis. 226 NFκB has been shown to be activated in human and androgen-independent prostate cancer cells. 227 The ubiquitin-proteasome pathway has been studied in prostate cancer as a regulator of the NFκB signal transduction pathway, downstream proapoptotic (bax) and antiapoptotic (bcl-2) protein expression, 226, 228, 229 and cell cycle regulatory proteins. 230 The recently discovered proteasome inhibitor PS-341 (bortezomib [Velcade]) has been associated with decreased production of bcl-2, inhibition of NFκB, and prevention of acquired resistance to chemotherapy in prostate cancer experimental systems. 231 NFκB overexpression in prostate cancer recently has been linked to adverse disease outcome. 232, 233 
Transcriptional Profiling
In the past several years, transcriptional profiling of clinical specimens has been introduced as a method for discovering new biomarkers of the disease and for the prediction of its outcome. [217] [218] [219] [220] [221] [222] [223] [234] [235] [236] [237] Although the bioinformatic methods necessary to evaluate the large data sets associated with these procedures have not been standardized, significant common findings 238 indicate that this technology holds substantial promise for the discovery of new prognostic factors that may be used in the future to predict the outcome of the disease and permit more individualized selection of primary therapy.
Conclusions
The major prognostic markers described in this review are summarized according to their current clinical use in Table 1 . The classic morphologic feature-based factors of tumor type, grade, volume, and stage are used widely and generally considered to be the standard of practice. The Ki-67 cell proliferation index, p53 and bcl-2 immunostaining, and DNA ploidy analysis also are used in many laboratories as adjuncts for predicting outcome in the disease. The remaining prognostic and predictive markers discussed in this review continue to be under evaluation to assess their usefulness in determining prognosis and guiding the selection of therapy for the disease. 
